Article information
Abstract
Scalp lesions are common in psoriasis and difficult to treat. Scientific evidence on the topic is scant and fragmentary, especially with respect to long-term treatment. This consensus statement is based on a critical assessment of the results of a MEDLINE search for clinical trials of the efficacy and safety of therapies used to treat scalp psoriasis. The recommendations were developed by an expert panel using the Delphi process to reach a consensus and then ratified by the members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. The recommended induction therapy for scalp psoriasis is either a topical corticosteroid or a topical treatment combining calcipotriol and betamethasone. The choice of an appropriate vehicle is crucial in improving effectiveness and patient adherence to treatment. The only formulations that have been studied in the long-term treatment of scalp psoriasis are a combination of calcipotriol and betamethasone in gel and calcipotriol alone in solution.
Keywords:
Psoriasis
Scalp
Treatment
Process
Delphi
Topical corticosteroids
Calcipotriol
Resumen
La afectación del cuero cabelludo resulta frecuente y de difícil tratamiento en los pacientes con psoriasis, siendo escasa y poco sistematizada la evidencia científica al respecto, en particular por lo que se refiere al tratamiento a largo plazo. En el presente documento de consenso, basado en una búsqueda (MEDLINE) de los ensayos clínicos publicados sobre la eficacia y seguridad de los diferentes tratamientos para la psoriasis del cuero cabelludo y su evaluación, se establecen unas recomendaciones, partiendo de un consenso Delphi por parte de un panel de expertos, refrendado por los miembros del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología. El tratamiento de inducción recomendado para la psoriasis del cuero cabelludo son los corticoides tópicos y la combinación de calcipotriol/betametasona. La elección de un vehículo apropiado es decisiva para incrementar la eficacia y el cumplimiento del paciente. Únicamente la combinación de calcipotriol/betametasona en gel y el calcipotriol en solución se han estudiado en el tratamiento de la psoriasis del cuero cabelludo a largo plazo.
Palabras clave:
Psoriasis
Cuero cabelludo
Tratamiento
Consenso
Delphi
Corticoesteroides tópicos
Calcipotriol
Full text is only aviable in PDF
References
[1.]
E.M. Farber, L. Nail.
Natural history and treatment of scalp psoriasis.
Cutis, 49 (1992), pp. 396-400
[2.]
P.C. Van de Kerkhof, M.E. Franssen.
Psoriasis of the scalp. Diagnosis and Management.
Am J Clin Dermatol, 2 (2001), pp. 159-165
[3.]
J. Sola-Ortigosa, M. Sánchez-Regaña, P. Umbert-Millet.
Psoriasis del cuero cabelludo.
Actas Dermosifiligr, 100 (2009), pp. 536-543
[4.]
P.C. Van de Kerkhof, D. de Hoop, J. de Korte, M.V. Kuipers.
Scalp psoriasis, clinical presentations and therapeutic management.
Dermatology, 197 (1998), pp. 326-334
[5.]
V.M. Heydendael, C.A. de Borgie, P.L. Spuls, P.M. Bossuyt, J.D. Bos, M.A. de Rie.
The burden of psoriasis is not determined by disease severity only.
J Investig Dermatol Symp Proc, 9 (2004), pp. 131-135
[6.]
R. Harbour, J. Miller, For the Scottish Intercollegiate Guidelines Network Grading Review Group.
A new system for grading recommendations in evidence based guidelines.
BMJ, 323 (2001), pp. 334-336
[7.]
C.S. Chan, A.S. Van Voorhees, M.G. Lebwohl, N.J. Korman, M. Young, B.F. Bebo, et al.
Treatment of severe scalp psoriasis: from the medical board of the National Psoriasis Foundation.
J Am Acad Dermatol, 60 (2009), pp. 962-971
[8.]
K. Papp, J. Berth-Jones, K. Kragballe, G Wozel, de la Brassinne.
Scalp psoriasis: a review of current topical treatments options.
J Eur Acad Dermatol Venereal, 21 (2007), pp. 1151-1160
[9.]
A.R. Mason, J. Mason, M. Cork, G. Dooley, G. Edwards.
Topical treatments for chronic plaque psoriasis.
Cochrane Database Sys Re, (2009),
[10.]
J. Ortonne, S. Chimenti, T. Luger, L. Puig, F. Reid, R. Trüeb.
Scalp psoriasis: European consensus on grading and treatment algorithm.
J Eur Acad Dermatol Venereol, 23 (2009), pp. 1435-1444
[11.]
J. Jones, D. Hunter.
Consensus methods for medical and health services research.
BMJ, 311 (1995), pp. 376-380
[12.]
D. Atkins, D. Best, P.A. Briss, M. Eccles, Y. Falck-Ytter, S. Flottorp, et al.
Grading quality of evidence and strength of recommendations.
BMJ, 328 (2004), pp. 1490
[13.]
G.H. Guyatt, A.D. Oxman, G.E. Vist, R. Kunz, Y. Falck-Ytter, P. Alonso-Coello, et al.
GRADE Working Group GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.
BMJ, 336 (2008), pp. 924-926
[14.]
T. Frederiksson, U. Pettersson.
Severe psoriasis—oral therapy with a new retinoid.
Dermatologica, 157 (1978), pp. 238-244
[15.]
K. Reich, U. Mrowietz.
Treatment goals in psoriasis.
J Dtsch Dermatol Ges, 5 (2007), pp. 566-574
[16.]
D. Thaçi, W. Daiber, W.H. Boehncke, R. Kaufmann.
Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3396 patients.
Dermatology, 203 (2001), pp. 153-156
[17.]
J. Choi, J.Y. Koo.
Quality of life issues in psoriasis.
J Am Acad Dermatol, 49 (2003), pp. S57-S61
[18.]
J.E. Ware, M. Kosinski, D.M. Turner-Bowker, B. Gandek.
How to score version 2 of the SF-36 Health Survey.
QualityMetric Incorporated, Lincoln, Rhode Island, (2000),
[19.]
M. Jones-Caballero, P. Fernández-Peñas, A. García-Díez, M.M. Chren, X. Badía.
La versión española de Skindex-29. Un instrumento de medida de la calidad de vida en pacientes con enfermedades cutáneas.
Med Clin (Barc), 118 (2002), pp. 5-9
[20.]
S.C. Chen, J. Yeung, M.M. Chren.
Scalpdex: a quality-of-life instrument for scalp dermatitis.
Arch Dermatol, 138 (2002), pp. 803-807
[21.]
M. Lebwohl.
A clinician’s paradigm in the treatment of psoriasis.
J Am Acad Dermatol, 53 (2005), pp. S59-S69
[22.]
J.E. Frangos, A.B. Kimball.
Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses.
Expert Opin Pharmacother, 9 (2008), pp. 2001-2007
[23.]
M.I. Lepaw.
Double-blind comparison of halcinonide solution and placebo control in treatment of psoriasis of the scalp.
Cutis, 21 (1978), pp. 571-573
[24.]
E.A. Olsen, D.L. Cram, J.G. Hickman, C. Jacobson, E.E. Jenkins, A.E. Lasser, et al.
A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis.
J Am Acad Dermatol, 24 (1991), pp. 443-447
[25.]
M. Pauporte, H. Maibach, N. Lowe, M. Pugliese, D.J. Friedman, H. Mendelsohn, et al.
Fluocinolone acetonide topical oil for scalp psoriasis.
J Dermatolog Treat, 15 (2004), pp. 360-364
[26.]
M. Jarrat, D. Breneman, A.B. Gottlieb, Y. Poulin, Y. Liu, V. Foley.
Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis.
J Drugs Dermatol, 3 (2004), pp. 367-373
[27.]
T.J. Franz, D.A. Parsell, R.M. Halualani, J.F. Hannigan, J.P. Kalbach, S. Harkonen.
Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy.
Int J Dermatol, 38 (1999), pp. 628-632
[28.]
L. Andreassi, A. Giannetti, M. Milani.
Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis. An open, multicentre, randomized, controlled, cross-over study on 241 patients.
Br J Dermatol, 148 (2003), pp. 134-138
[29.]
H.I. Katz, J.S. Lindholm, J.S. Weiss, J.S. Shavin, M. Morman, R. Bressinck, et al.
Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis.
Clin Ther, 17 (1995), pp. 390-401
[30.]
D.L. Breneman, M. Davis, V. Berger, R. Chaney.
A double blind trial comparing the efficacy and safety of augmented betamethasone dipropionate lotion with fluocinonide solution in the treatment of severe scalp psoriasis.
J Dermatol Treat, 3 (1992), pp. 19-21
[31.]
S.R. Feldman, S.M. Ravis, A.B. Fleischer, A. McMichael, E. Jones, R. Kaplan, et al.
Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single-blind, open-label study in the treatment of scalp psoriasis.
J Cutan Med Surg, 5 (2001), pp. 386-389
[32.]
D.E. Vanderploeg, R.C. Cornell, R. Binder, J.S. Weintraub, M. Jarrat, M.L. Jones, et al.
Clinical trial in scalp psoriasis. Mometasone furoate 0.1% applied once daily vs betamethasone valerate lotion 0.1% applied twice daily.
Acta Ther, 15 (1989), pp. 145-152
[33.]
J.M. Swinehart, J.R. Barkoff, D. Dvorkin, G. Fisher, E. Peets.
Mometasone furoate lotion once daily versus triamcinolone acetonide lotion twice daily in psoriasis.
Int J Dermatol, 28 (1989), pp. 680-681
[34.]
P. Reygagne, U. Mrowietz, J. Decroix, F.B. de Waard-van der Spek, L.O. Acebes, A. Figueiredo, et al.
Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis.
J Dermatolog Treat, 16 (2005), pp. 31-36
[35.]
M.R. Klaber, P.E. Hutchinson, A. Pelvis-Leftick, K. Kragballe, T.L. Reunala, P.C. van de Kerkhof, et al.
Comparative effects of calcipotriol solution (50 micrograms/mL) and betamethasone 17-valerate solution (1mg/mL) in the treatment of scalp psoriasis.
Br J Dermatol, 131 (1994), pp. 678-683
[36.]
C.E. Griffiths, A.Y. Finlay, C.J. Fleming, J.N. Barrer, F. Mizzi, S. Arsonnaud.
A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis.
J Dermatolog Treat, 17 (2006), pp. 90-95
[37.]
L. Hillström, L. Pettersson, L. Svensson.
Comparison of betamethasone dipropionate lotion with salicylic acid (Diprosalic) and clobetasol propionate lotion (Dermovate) in the treatment of psoriasis of the scalp.
J Int Med Res, 10 (1982), pp. 419-422
[38.]
P. Andres, M. Poncet, S. Farzaneh, P. Soto.
Short-term safety assessment of clobetasol propionate 0.05% shampoo: hypothalamic-pituitary-adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis.
J Drugs Dermatol, 5 (2006), pp. 328-332
[39.]
A. Lassus.
Local treatment of psoriasis of the scalp with clobetasol propionate and betamethasone-17,21-dipropionate: a double-blind comparison.
Curr Med Res Opin, 4 (1976), pp. 365-367
[40.]
H. Bovenschen, P. van de Kerkhof.
Treatment of scalp psoriasis with clobetasol-17 propionate 0.05% shampoo: a study on daily clinical practice.
J Eur Acad Dermatol Venereol, 24 (2010), pp. 439-444
[41.]
J. Tan, R. Thomas, B. Wang, D. Gratton, R. Vender, N. Kerrouche, et al.
Short-contact clobetasol propionate shampoo 0.05% improves quality of life in patients with scalp psoriasis.
Cutis, 83 (2009), pp. 157-164
[42.]
K. Kragballe, I.L. Wildfang.
Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes.
Arch Dermatol Res, 282 (1990), pp. 164-167
[43.]
C. Green, M. Ganpule, D. Harris, G. Kavanagh, C. Kennedy, R. Mallet, et al.
Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp.
Br J Dermatol, 130 (1994), pp. 483-487
[44.]
M.R. Klaber, C. McKinnon.
Calcipotriol (Dovonex®) scalp solution in the treatment of scalp psoriasis: comparative efficacy with 1% coal tar/1% coconut oil/0.05% salicylic acid (Capasal®) shampoo, and long-term experience.
J Dermatolog Treat, 11 (2000), pp. 21-28
[45.]
G.A. Duweb, O. Abuzariba, M. Rahim, M. Al-Taweel, S.A. Abdulla.
Scalp psoriasis: topical calcipotriol 50 μg/g/ml solution vs betamethasone valerate 1% solution.
Int J Clin Pharmacol Res, 20 (2000), pp. 65-68
[46.]
S. Emaitig, M. Alyazachi, A. Bashir, G. Duweb.
Calcipotriol solution vs. betamethasone and salicylic acid solution in the treatment of scalp psoriasis.
J Eur Acad Dermatol Venereol, 18 (2004), pp. 262
[47.]
C. Barrett, D. Lowson, K.J. Blades.
Limited benefit of combined use of tar-based shampoo with 50 mg/ml calcipotriol solution in scalp psoriasis.
J Dermatol Treat, 16 (2005), pp. 175
[48.]
T. Ruzicka, C. Trompke.
Behandlung der Kopfhaut-Psoriasis. Gute Wirksamkeit und Sicherheit durch Tacalcitol-Emulsion.
Hautarzt, 55 (2004), pp. 165-170
[49.]
L. Barnes, P. Altmeyer, L. Fôrstrôm, M.H. Stenström.
Long-term treatment of psoriasis with calcipotriol scalp solution and cream.
Eur J Dermatol, 10 (2000), pp. 199-204
[50.]
J. Faergemann, U. Diehl, L. Bergfelt, A. Brodd, B. Edmar, K. Hersle, et al.
Scalp psoriasis: synergy between the Malassezia yeasts and skin irritation due to calcipotriol.
Acta Derm Venereol, 83 (2003), pp. 438-441
[51.]
C.A. Ramsay, J. Berth-Jones, G. Brundin, W.J. Cunliffe, L. Dubertret, P.C. Van de Kerkhof, et al.
Long-term use of topical calcipotriol in chronic plaque psoriasis.
Dermatology, 189 (1994), pp. 260-264
[53.]
K. Kragballe, P.C. Van de Kerkhof.
Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis.
J Eur Acad Dermatol Venereol, 20 (2006), pp. 39-44
[54.]
N. Cassano, G.A. Vena.
Treatment of scalp psoriasis with betamethasone dipropionate and calcipotriol two-compound product.
Acta Derm Venereol, 87 (2007), pp. 85-86
[55.]
A.M. Downs.
Dovobet ointment under occlusion overnight for troublesome scalp psoriasis.
Acta Derm Venereol, 86 (2006), pp. 57-58
[56.]
R.M. Emerson, C. Howlett.
Successful treatment of scalp psoriasis with Dovobet® ointment.
Br J Dermatol, 151 (2004), pp. 52-53
[57.]
C. Buckley, V. Hoffmann, J. Shapiro, S. Saari, F. Cambazard, M. Milsgaard.
Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: A phase II study.
Dermatology, 217 (2008), pp. 107-113
[58.]
G.B.E. Jemec, C. Ganslandt, J.P. Ortonne, Y. Poulin, A.D. Burden, P. de Unamuno, et al.
A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
J Am Acad Dermatol, 59 (2008), pp. 455-463
[59.]
P.C.M. Van de Kerkhof, V. Hoffmann, A. Anstey, L. Barnes, C. Bolduc, K. Reich, et al.
A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
Br J Dermatol, 160 (2009), pp. 170-176
[60.]
S. Tyring, A. Bibby.
Calcipotrione/betamethasone dipropionate gel compared to gel vehicle in treating scalp psoriasis in Hispanic/Latino and black/African American patients.
J Am Acad Dermatol, 58 (2008),
[61.]
J.P. Ortonne, C. Ganslandt, J. Tan, P. Nordin, K. Kragballe, S. Segaert.
Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial.
J Eur Acad Dermatol Venereol, 23 (2009), pp. 919-926
[62.]
K. Kragballe, V. Hoffmann, J.P. Ortonne, J. Tan, P. Nordin, S. Segaert.
Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial.
Br J Dermatol, 161 (2009), pp. 159-166
[63.]
T.A. Luger, F. Cambazard, F.G. Larsen, M. Bourcier, G. Gupta, F. Clonier, et al.
A study of the safety of efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis.
Dermatology, 217 (2008), pp. 321-328
[64.]
J.L. López Estebaranz.
Tratamiento local de la psoriasis del cuero cabelludo del adulto.
Monogr Dermatol, 22 (2009), pp. 55-60
[65.]
S.M. Going, B.M. Guyer, D.R. Jarvie, J.A. Hunter.
Salicylic acid gel for scalp psoriasis.
Clin Exp Dermatol, 11 (1986), pp. 260-262
[66.]
A. Langner, H. Wolska, P. Hebborn.
Treatment of psoriasis of the scalp with coal tar gel and shampoo preparations.
Cutis, 32 (1983), pp. 290-296
[67.]
A. McGill, A. Frank, N. Emmett, D.M. Turnbull, M.A. Birch-Machin, N.J. Reynolds.
The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory component mitochondria.
FASEB J, 19 (2005), pp. 1012-1024
[68.]
A. Wulff-Woesten, D. Ohlendorf, B.M. Henz, N. Haas.
Dithranol in an emulsifying oil base (bio-wash-oil) for the treatment of psoriasis of the scalp.
Skin Pharmacol Physiol, 17 (2004), pp. 91-97
[69.]
H.P. Gollnick, A.F. Finzi, R. Marks, J.N. Barker, C. Jansen, J. Revuz, et al.
Optimising the use of tazarotene in clinical practice: consensus statement from the European advisory panel for tazarotene (Zorac TM).
Dermatology, 199 (1999), pp. 40-46
[70.]
E. Gueho, T. Boekhout, H.R. Ashbee, J. Guillot, A. Van Belkum, J. Faergemann.
The role of the Malassezia species in the ecology of human skin and as pathogens.
Med Mycol, 36 (1998), pp. 220-229
[71.]
R.B. Warren, B.C. Brown, C.E. Griffiths.
Topical treatment for scalp psoriasis.
Drugs, 68 (2008), pp. 2293-2302
[72.]
A. Shemer, N. Nathansohn, B. Kaplan, G. Weiss, N. Newman, H. Trau.
Treatment of scalp seborrheic dermatitis and psoriasis with an ointment of 40% urea and 1% bifonazole.
Int J Dermatol, 39 (2000), pp. 532-534
[73.]
C.S. Jury, L. McHugh, G.S. Shankland, A.D. Burden.
A randomized, placebo-controlled trial of oral itraconazole in scalp psoriasis.
J Dermatol Treat, 11 (2000), pp. 85-89
[74.]
J. Faergemann, U. Diehl, L. Bergfelt, A. Brodd, B. Edmar, K. Hersle, et al.
Scalp psoriasis: synergy between the Malassezia yeasts and skin irritation due to calcipotriol.
Acta Derm Venereol, 83 (2003), pp. 438-441
[75.]
L.A. Wheeler, M.D. Saperstein, N.J. Lowe.
Mutagenicity of urine from psoriatic patients undergoing treatment with coal tar and ultraviolet light.
J Invest Dermatol, 77 (1981), pp. 181-185
[76.]
S.H. Yuspa.
Cutaneous chemical carcinogenesis.
J Am Acad Dermatol, 15 (1986), pp. 1031-1044
[77.]
C. Johnson, B. Edison, I. Brouda, B. Green.
A novel LCD (coal tar) solution for psoriasis does not discolor naturally light or color-processed hair in an exaggerated exposure test model.
J Cosmet Dermatol, 8 (2009), pp. 211-215
[78.]
J.M. Carrascosa, F. Vanaclocha, L. Borrego, E. Fernández-López, A. Fuertes, L. Rodríguez-Fernández-Freire, et al.
Revisión actualizada del tratamiento tópico de la psoriasis. Documento de Consenso.
Actas Dermosifiliogr, 100 (2009), pp. 190-200
[79.]
T.M. Dando, K. Wellington.
Topical tazarotene: a review of its use in the treatment of plaque psoriasis.
Am J Clin Dermatol, 6 (2005), pp. 255-272
[80.]
C.R. Taylor, A.L. Racette.
A 308-nm excimer laser for the treatment of scalp psoriasis.
Lasers Surg Med, 34 (2004), pp. 136-140
[81.]
L.K. Dotterud, R. Braun.
UV-B comb versus betamethasone solution in scalp psoriasis.
Tidsskr Nor Laegeforen, 120 (2000), pp. 1858-1859
[82.]
B. Lindelöf, A. Johannesson.
Psoriasis of the scalp treated with Grenz rays or topical corticosteroid combined with Grenz rays. A comparative randomized trial.
Br J Dermatol, 119 (1988), pp. 241-244
[83.]
A. García Díez.
Tratamiento sistémico de la psoriasis del cuero cabelludo.
Monogr Dermatol, 22 (2009), pp. 61-66
[84.]
V.M. Heydendael, P.I. Spuls, B.C. Opmeer, C.A. de Boggie, J.B. Reitsma, W.F. Goldschmidt, et al.
Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.
N Engl J Med, 349 (2003), pp. 658-665
[85.]
I. Flyström, B. Stenberg, A. Svensson, I.M. Bergbrant.
Methotrexate vs ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial.
Br J Dermatol, 158 (2008), pp. 116-121
[86.]
J.H. Saurat, G. Stingl, L. Dubertret, K. Papp, R.G. Langley, J.P. Ortrone, et al.
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION).
Br J Dermatol, 158 (2008), pp. 558-566
[87.]
J. Koo.
A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporine, Neoral and Sandimmun, in patients with psoriasis.
Br J Dermatol, 139 (1998), pp. 88-95
[88.]
C.N. Ellis, M.S. Fradin, J.M. Messana, M.D. Brown, M.T. Siegel, A.H. Hartley, et al.
Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial.
N Eng J Med, 324 (1991), pp. 277-284
[89.]
K. Kragballe, C.T. Cansen, J.M. Geiger, J.R. Bjerke, E.S. Falk, L. Gip, et al.
A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study.
Acta Derm Venereol, 69 (1989), pp. 35-40
[90.]
D.J. Pearce, S. Klinger, K.K. Ziel, E.J. Murad, R. Rowell, S.R. Feldman.
Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis.
Arch Dermatol, 142 (2006), pp. 1000-1004
[91.]
P.J. Altmeyer, U. Matthes, F. Pawlak, K. Hoffmann, P.J. Frosch, P. Ruppert, et al.
Antipsoriatic effect of fumaric acid derivates. Results of a multicenter double-blind study in 100 patients.
J Am Acad Dermatol, 30 (1994), pp. 977-981
[92.]
H. Gollnick, P. Altmeyer, R. Kaufmann, J. Ring, E. Christophers, S. Pavel, et al.
Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris.
Dermatology, 205 (2002), pp. 46-53
[93.]
K.B. Gordon, R.G. Langley, C. Leonardi, D. Toth, M.A. Menter, S. Kang, et al.
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: a double-blind, randomized controlled trial and open-label extension study.
J Am Acad Dermatol, 55 (2006), pp. 598-606
[94.]
A. Menter, S.K. Tyring, K. Gordon, A.B. Kimball, C. Leonardi, R.G. Langley, et al.
Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial.
J Am Acad Dermatol, 58 (2008), pp. 106-115
[95.]
D. Thaçi, A. Khemis, Ghislain P.-D., P. Arenberger, K. Kragballe, J.-H. Saurat, et al.
Adalimumab plus topical treatment (calcipotriol/beta-methasone) in the treatment of moderate to severe psoriasis - Effects on skin, scalp, and nails: Results from BELIEVE.
18th Congress of the European Academy of Dermatology and Venereology (EADV), Berlin,
[96.]
A.B. Gottlieb, R.T. Matheson, N. Lowe, G.G. Krueger, S. Kang, B.S. Goffe, et al.
A randomized trial of etanercept as monotherapy for psoriasis.
Arch Dermatol, 139 (2003), pp. 1627-1632
[97.]
C.L. Leonardi, J.L. Powers, R.T. Matheson, B.S. Goffe, R. Zitnik, A. Wang, et al.
Etanercept as monotherapy in patients with psoriasis.
N Eng J Med, 349 (2003), pp. 2014-2022
[98.]
K.A. Papp, S. Tyring, M. Lahfa, J. Prinz, C.E. Griffiths, A.M. Nakanishi, et al.
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
Br J Dermatol, 152 (2005), pp. 1304-1312
[99.]
S. Tyring, A. Gottlieb, K. Papp, K. Gordon, C. Leonardi, A. Wang, et al.
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.
Lancet, 367 (2006), pp. 29-35
[100.]
J.P. Ortonne, R. Strohal, E. Dauden, D. Robertson, R. Pedersen, C. Molta.
Etanercept treatment for up to 54 weeks sustain scalp improvement in patients with moderate to severe psoriasis: Results of the Crystel Study.
5th European Academy of Dermatology and Venereology (EADV) Spring Symposium, Istanbul, pp. 22-25
[101.]
U. Chaudari, P. Romano, L.D. Mulcahy, L.T. Dooley, D.J. Baker, A.B. Gottlieb.
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.
Lancet, 357 (2001), pp. 1842-1847
[102.]
A.B. Gottlieb, R. Evans, S. Li, T. Dooley, C.A. Guzzo, D. Baker, et al.
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial.
J Am Acad Dermatol, 51 (2004), pp. 534-542
[103.]
J.P. Ortonne.
Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis.
J Eur Acad Dermatol Venereol, 17 (2003), pp. 12-16
[104.]
C.H. Gribetz, R. Blum, C. Brady, S. Cohen, M. Lebwohl.
An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis.
J Am Acad Dermatol, 53 (2005), pp. 73-75
[105.]
J. Krell, C. Nelson, L. Spencer, S. Miller.
An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis.
J Am Acad Dermatol, 58 (2008), pp. 609-616
[106.]
C.L. Leonardi, A.B. Kimball, K.A. Papp, N. Yeilding, C. Guzzo, Y. Wang, For the PHOENIX 1 Study Investigators, et al.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double blind, placebo-controlled trial (PHOENIX 1).
Lancet, 371 (2008), pp. 1665-1674
[107.]
K. Papp, R.G. Langley, R. Lebwohl, G.G. Krueger, P. Szapary, N. Yeilding, For the PHOENIX 2 Study Investigators, et al.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double blind, placebo-controlled trial (PHOENIX 2).
Lancet, 371 (2008), pp. 1675-1684
[108.]
L. El Shabrawi-Caelen, M. La Placa, C. Vincenci, T. Haidn, R. Muelleger, A. Tosti.
Adalimumab-induced psoriasis of the scalp with diffuse alopecia: A severe potentially irreversible cutaneous side effect of TNF-alpha blockers.
Inflamm Bowel Dis, 16 (2010), pp. 182-183
[109.]
B.L. Barlett, S.K. Tyring.
Ustekinumab for chronic plaque psoriasis.
Lancet, 371 (2008), pp. 1639-1640
Copyright © 2010. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
